Matthew Sherman - Pulmatrix Insider

PULM -- USA Stock  

USD 0.49  0.0002  0.041%

  Director
Dr. Matthew L. Sherman, M.D. serves as Director of the Company. Dr. Sherman has served as Chief Medical Officer of Acceleron Pharma, Inc. since May 2006 and as Executive Vice President Acceleron Pharma, Inc. since March 2015. Prior to joining Acceleron, he served as Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals where he was responsible for clinical research, clinical operations, biostatistics, data management, regulatory affairs, quality assurance and program management. Prior to that, Dr. Sherman worked at Genetics Institute and Wyeth Pharmaceuticals in various capacities including Therapeutic Area Director for Oncology. While at Wyeth, Dr. Sherman provided senior oncology and hematology leadership for worldwide clinical development for both small molecule and biologic therapeutics, including the submission and approval of Mylotarg by the FDA. He has published numerous papers and book chapters in the field of oncology and clinical development and is named as an inventor of several patents. Dr. Sherman is board certified in Medical Oncology and Internal Medicine and held various clinical positions at Harvard Medical School with corresponding hospital appointments at the DanaFarber Cancer Institute and Brigham and Womens Hospital. Dr. Sherman received an SB in chemistry from the Massachusetts Institute of Technology and an M.D. from Dartmouth Medical School
Age: 61  Director Since 2016      
781-357-2333  http://pulmatrix.com
Sherman brings to the Board his medical background and extensive experience as a biopharmaceutical industry leader in clinical research and development.

Matthew Sherman Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (65.98) % which means that it has lost $65.98 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (168.96) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 2.52 M in liabilities with Debt to Equity (D/E) ratio of 33.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix has Current Ratio of 0.32 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Michael BlaszykNantKwest
2015
Bruce PeacockDicerna Pharmaceuticals
2014
Napoleone FerraraDelMar Pharmaceuticals
2018
Berndt ModigAuris Medical Holding AG
2015
Alfred NovakDova Pharmaceuticals
2017
Kurt ContiEdge Therapeutics
2010
Loch MacdonaldEdge Therapeutics
2009
Natale RicciardiDynavax Technologies Corporatio
2013
William GarnerDelMar Pharmaceuticals
2013
Steven GoldmanDova Pharmaceuticals
2017
Robert TothDelMar Pharmaceuticals
2013
Mats BlomAuris Medical Holding AG
2018
John ThomasNantKwest
2014
Robert SpiegelEdge Therapeutics
2013
Colin GoddardEndocyte
2013
Robert RosenNantKwest
N/A
John PottsNantKwest
2014
Stanley PlotkinDynavax Technologies Corporatio
2005
Dennis CarsonDynavax Technologies Corporatio
1997
Rosemary CraneEdge Therapeutics
2017
James LoughlinEdge Therapeutics
2011

Entity Summary

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 24 people.Pulmatrix (PULM) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 24 people. Pulmatrix was previously known as PULMATRIX INC and was traded on BATS Exchange under the symbol RTGN. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.

Pulmatrix Leadership Team

Terrance McGuire, Director
Matthew Sherman, Director
David Hava, Chief Scientific Officer
Akihisa Akao, Director
James Roach, Chief Medical Officer
Michael Higgins, Director
Steven Gillis, Director
Jean Sung, Vice President - Pharmaceutical Development
William Duke, CFO, Principal Financial Officer & Principal Accounting Officer
Robert Clarke, CEO and President and Director
Scott Rocklage, Director
Kurt Graves, Director
Richard Conley, Independent Director
Mark Iwicki, Chairman of the Board
Amit Munshi, Director
Gregory French, Independent Director
David JD, Advisor

Stock Performance Indicators

Current Sentiment - PULM

Pulmatrix Investor Sentiment
Most of Macroaxis users are at this time bullish on Pulmatrix. What is your perspective on investing in Pulmatrix? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip
Currently Active Assets on Macroaxis
MSFT   
Purchased over 20 shares of
2 days ago
Traded for 106.27
F   
Purchased over 200 shares of
2 days ago
Traded for 10.56
GM   
Purchased over 70 shares of
2 days ago
Traded for 39.4
GOOG   
Purchased few shares of
2 days ago
Traded for 1184.91
C   
Purchased over 40 shares of
2 days ago
Traded for 69.22
Additionally take a look at Your Equity Center. Please also try Money Flow Index module to determine momentum by analyzing money flow index and other technical indicators.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">